Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, has raised a $25M Series A — Altis Labs, an AI software company for drug development, raised a $25 million Series A, CEO Felix Baldauf-Lenschen tells Axios Pro.
Posted from: this blog via Microsoft Power Automate.